SEATTLE, May 18 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) today announced upcoming presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29-June 2, 2009 in Orlando, Florida. Abstracts related to our product candidates Stimuvax(R), PX-866 and PX-12 are now available to the public online at the ASCO Web site, www.abstract.asco.org.
Abstracts include: - "Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)" - Abstract No: 3055 Poster session: Developmental Therapeutics: Immunotherapy - Saturday May 30, 8:00 AM to 12:00 PM, Level 2, West Hall C - "Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor" - Abstract No: 3542 Poster session: Developmental Therapeutics: Molecular Therapeutics - Saturday May 30, 8:00 AM to 12:00 PM Level 2, West Hall C - "Results from phase Ib studies of PX-12, a thioredoxin inhibitor in patients with advanced solid malignancies" - Abstract # 2571, Poster Session: Developmental Therapeutics: Cytotoxic Chemotherapy - Saturday May 30, 8:00 AM to 12:00 PM, Level 2, West Hall C
Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.
|SOURCE Oncothyreon Inc.|
Copyright©2009 PR Newswire.
All rights reserved